ipod buy |
||||||
|
News for 19-Oct-26 Source: MedicineNet Diabetes General Source: MedicineNet High Blood Pressure General Source: MedicineNet High Blood Pressure General Source: MedicineNet Diabetes General Source: MedicineNet High Blood Pressure General Source: MedicineNet High Blood Pressure General Source: MedicineNet High Blood Pressure General Source: MedicineNet Diabetes General Source: MedicineNet High Blood Pressure General Source: MedicineNet Diabetes General
|
The Best ipod buy websiteAll the ipod buy information you need to know about is right
here. Presented and researched by http://www.mdnewscast.net. We've searched
the information super highway far and wide to provide you with the
best ipod buy site on the internet today. The links below will
assist you in your efforts to find the information that you are looking
for about
ipod buy
ipod buy - high quality sitesWhen you’re looking for information on buying ipod buy it can all seem very overwhelming. But don’t worry, because we’ve sorted through all the ipod buy sites on the internet and have found the very best ones that will get you what you want, how you want it. We know how important it is to be informed when you’re looking for ipod buy. Some websites are better than others and will meet your ipod buy needs in a better fashion. When you’re looking for a high quality ipod buy site you know you can rely on, we recommend the above web site. We have taken the hard work out of your ipod buy shopping and narrowed our list of ipod buy websites down to only those of the very best. Knowing you’re getting value for money is very important in buying ipod buy, so by coming to this web site you can rest with the sound knowledge that you are getting the ipod buy you paid for. By buying through our recommend links you can also rest assured your ipod buy will be of the highest quality. How do we know? Because when we’re shopping for ipod buy ourselves it’s where we go. You might wonder why we’re suggesting you click on some outside links rather than stay on our ipod buy site. Well it’s because we’ve only just put this site up and haven’t yet got it fully operational. Our aim is to be the best site for ipod buy info on the net, and I’m sure that one day soon we’ll achieve it. So please bookmark us and come back soon. Meanwhile please follow one of the links. ipod buy
Thousands of ipod buy e-stores now thrive on the Web, providing people with a way to purchase goods and services electronically. For small businesses, the Internet can deliver a global market. Depending on which survey you believe, that may be more than 350 million people, with another 500 million Internauts projected over the next few years. If the demographics of the online community match your ipod buy customer profile, that's a lot of potential new business. While the potential is there, however, challenges loom large. Remember, it takes time for people to adopt to new technology and modes of transactions. Many people remain reluctant to give out their credit card numbers over the Internet for ipod buy purchases. But most analysts project healthy growth for ipod buy online sales, especially as security issues are addressed. Drug Offers Hope to Cancer Patients by: ARA Content
(ARA) - A decade ago, research into angiogenesis-inhibiting compounds was still in a relative state of infancy. The principle itself was not new -- as far back as the early '70s, there was speculation that human cancer tumors could not grow beyond a few millimeters in diameter without obtaining their own blood supply. But opinion was still divided in the scientific community. Angiogenesis itself is a natural and necessary physiological function, which refers to the process by which new blood vessels form and develop. In its pathological form, however, angiogenesis is also implicated in the progression of more than 20 different diseases, including cancer. In order to grow, solid tumors need to be supplied by blood vessels that act as conduits for oxygen and nutrients. Once a vascular network has been generated around a tumor, cancerous cells can then invade the rest of the body, a process called metastasis. Angiogenesis inhibitors block the formation of new blood vessels, without which cancerous cells are starved and tumors cannot grow. In recent years, the therapeutic potential of angiogenesis inhibitors has gained wide acceptance. Indeed, the scientific community now believes that more than 90 percent of all cancer cases are angiogenesis dependent. The industry spends nearly $4 billion annually in angiogenic research and more than 100 research organizations and companies are currently developing angiogenesis-blocking drugs. Æterna Laboratories Inc. is at the forefront of this effort. In fact, it is one of the very few biotechnology companies in the world with an angiogenesis-blocker in Phase lll clinical development. Its proprietary compound, Neovastat, is currently the subject of Phase III trials in lung and kidney cancer and a Phase ll trial in multiple myeloma, a form of blood cancer. Neovastat possesses multiple mechanisms of action that counteract the angiogenic process. Among competing products, this makes it unique. It has also shown an excellent safety profile in clinical trials. Further advantages of Neovastat are that it is orally administered, which makes it convenient for patients who must receive treatment on a long-term basis, and it may be taken in association with standard therapies such as chemotherapy. Angiogenesis blockers are not a cure for cancer. They are a form of treatment -- in the same way that insulin is a treatment for diabetes -- that should allow patients to lead a more normal life, without suffering from the often debilitating side-effects that some treatments can produce. Æterna's clinical trials strategy has targeted forms of cancer for which there is an urgent need for new therapies. Since 1996, Neovastat has been tested in more than 850 patients in North American and European countries. Currently, Neovastat is the subject of three clinical trials, targeting three forms of cancer. For multiple myeloma, the second most common form of blood cancer, the drug is in Phase II trials with 125 patients in the United States, Canada and Europe. This trial should be completed in early 2003. For progressive renal cell carcinoma, the drug is in Phase III trials with 302 patients in the United States, Canada and Europe, which should be completed in early 2003. For non-small cell lung cancer, Neovastat is in a Phase III trial sponsored by the National Cancer Institute with 760 patients in the United States and Canada. This trial should be completed in 2005. Once the clinical trials are complete, health authorities in various countries can then assess these results and make decisions on approval.
|
|||||
|
http://www.medmeet.com/ |
||||||
| Fantasy Football Strategies Medical Meetings On The Net Medical Newscast |